Evidence map›Paper›PMID 36303225›Full record

ArticleOrphanet journal of rare diseases2022

Transitioning of protein substitutes in patients with phenylketonuria: evaluation of current practice.

Ozlem Yilmaz, Alex Pinto, Anne Daly, Catherine Ashmore, Sharon Evans, Nurcan Yabanci Ayhan, Anita MacDonald

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ozlem YilmazBirmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, UK. o.yilmaz@ybu.edu.tr.ORCID 0000-0002-2941-9505
Alex PintoBirmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, UK.
Anne DalyBirmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, UK.
Catherine AshmoreBirmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, UK.
Sharon EvansBirmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, UK.
Nurcan Yabanci AyhanDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Ankara University, Ankara, 06290, Turkey.
Anita MacDonaldBirmingham Women's and Children's NHS Foundation Trust, Birmingham, B4 6NH, UK. anita.macdonald@nhs.net.
Birmingham Women’s and Children’s NHS Foundation Trust · GBAnkara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn children with phenylketonuria (PKU), transitioning protein substitutes at the appropriate developmental age is essential to help with their long-term acceptance and ease of administration. We assessed the parental experiences in transitioning from a second stage to third stage liquid or powdered protein substitute in patients with PKU.

resultsSixteen interviews (23 open-ended questions) were carried out with parents/caregivers of children with PKU (8 females, 50%) with a median age of 8 years (range 5-11 years), continuously treated with diet, and on a third stage protein substitute. Parents/caregivers identified common facilitators and barriers during the third stage protein substitute transition process. The main facilitators were: child and parent motivation, parent knowledge of the transition process, a role model with PKU, low volume and easy preparation of the third stage protein substitute (liquid/powder), anticipation of increasing child independence, lower parent workload, attractive packaging, better taste and smell, school and teacher support, dietetic plans and guidance, PKU social events, child educational materials and written resources. The main barriers were child aversion to new protein substitutes, poor child behaviour, child aged > 5 years, parental fear of change, the necessity for  parental time and persistence, loss of parental control, high product volume, different taste, smell, and texture of new protein substitutes, and peer bullying.

conclusionA stepwise, supportive approach is necessary when transitioning from second to third stage protein substitutes in PKU. Future studies are needed to develop guidance to assist parents/caregivers, health professionals, and teachers during the transition process.

Indexed as

PhenylketonuriasCaregiversChildChild, PreschoolFemaleHumansParentsProteinsProteinsBarriersLiquidPhenylketonuriaPowderProtein substituteTransition

Identifiers

PMID36303225
PMCPMC9615388
OpenAlexW4307640653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.